Which has the lower trailing P/E, BIIB or DXCM?

DXCM has the lower trailing P/E: BIIB trades at 38.43 and DXCM at 32.82. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BIIB or DXCM?

Over the past five years, DXCM grew revenue faster — BIIB at a -3.19% CAGR versus DXCM at 18.03%.

Is BIIB or DXCM more profitable?

DXCM runs the higher net margin — BIIB at 8.39% versus DXCM at 20.12%.

How have BIIB and DXCM total returns compared?

Over the past 10 years, BIIB delivered -3.13% and DXCM delivered 13.78% annualized total return. Past performance doesn't predict future results.

Biogen Inc. (BIIB) vs DexCom, Inc. (DXCM)

A side-by-side comparison of Biogen Inc. and DexCom, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 10, 2026. Differences are shown without an overall score or investment verdict.

BIIB

Biogen Inc.

$32.08B

$217.15HealthcareDelayed quote: Sep 11, 2026, 4:00 PM EDT

DXCM

DexCom, Inc.

$31.33B

$83.03HealthcareDelayed quote: Sep 11, 2026, 4:00 PM EDT

Total return — BIIB vs DXCM

growth of $100 · dividends reinvested · last 10y

BIIB -31.0% (-3.6%/yr)DXCM +267.9% (+13.9%/yr)DXCM compounded faster over this window

Log scale — wide-divergence pair

BIIB DXCM

BIIB vs DXCM: by the numbers

•BIIB is the larger company ($32.08B vs $31.33B market cap).
•DXCM trades at the lower trailing earnings multiple (32.82 vs 38.43 P/E), one valuation lens rather than an overall verdict.
•DXCM converts more revenue to profit (20.12% vs 8.39% net margin).
•DXCM grew revenue faster over the past five years (18.03% vs -3.19% CAGR).

Metrics side by side

Valuation

Metric	BIIB	DXCM
P/E ratio	38.43	32.82
Forward P/E	17.39	31.13
P/S ratio	3.23	6.31
P/B ratio	1.70	11.95
EV / EBITDA	N/A	22.54
FCF yield	8.40%	4.48%

Profitability

Metric	BIIB	DXCM
Gross margin	67.71%	62.47%
Operating margin	12.79%	22.92%
Net margin	8.39%	20.12%
ROE	4.43%	38.14%
ROIC	4.28%	21.71%

Growth (annualized)

Metric	BIIB	DXCM
Revenue CAGR (5Y)	-3.19%	18.03%
EPS CAGR (5Y)	-18.67%	10.31%
FCF CAGR (5Y)	-11.63%	69.49%
Total return CAGR (5Y)	-6.40%	-9.26%

Frequently asked

Which has the lower trailing P/E, BIIB or DXCM?: DXCM has the lower trailing P/E: BIIB trades at 38.43 and DXCM at 32.82. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BIIB or DXCM?: Over the past five years, DXCM grew revenue faster — BIIB at a -3.19% CAGR versus DXCM at 18.03%.
Is BIIB or DXCM more profitable?: DXCM runs the higher net margin — BIIB at 8.39% versus DXCM at 20.12%.
How have BIIB and DXCM total returns compared?: Over the past 10 years, BIIB delivered -3.13% and DXCM delivered 13.78% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BIIB analysis Full DXCM analysis Interactive comparison tool

Dig into the metrics

Biogen P/E ratio DexCom P/E ratio Biogen ROE DexCom ROE Biogen operating margin DexCom operating margin Biogen revenue growth DexCom revenue growth Biogen free cash flow DexCom free cash flow

Biogen & DexCom appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 10, 2026.